Cannabis Science Inc (CBIS) 0.1640 $CBIS
Enertopia Announces Dr. Robert Melamede Ph.D. Joins Advisory Board
ACCESSWIRE - Wed Mar 26, 7:05AM CDT
VANCOUVER, BC / ACCESSWIRE / March 26, 2014 / Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the "Company" or "Enertopia") is very pleased to announce that Dr. Robert Melamede, Ph.D. and current President at Cannabis Science (CBIS) has joined the Advisory board of Enertopia.
Cannabis Science Finalizes $1 Million in New Financing
ACCESSWIRE - Wed Mar 19, 10:22AM CDT
A developer of cannabis-based pharmaceutical products Cannabis Science Inc. (NASDAQ OTC: CBIS) announced that it has finalized its $1,000,000 private placement and the funds have already been put into the bank.
Cannabis Science (CBIS) Applauds Unprecedented United States Federal Government Approval of University Study of Medical Cannabis for Veterans Suffering from PTSD
PR Newswire - Wed Mar 19, 9:03AM CDT
Cannabis Science, Inc. (NASDAQ OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds federal government approval of a University of Arizona study of efficacy of medical cannabis in treating post traumatic stress disorder (PTSD). Cannabis Science sees this approval by the U.S. Department of Health and Human Services as a watershed moment for federal authorization of medical cannabis research.
NTRR: Cannabis Market Growth Poised to Outpace Smartphones
Business Wire - Wed Mar 19, 4:00AM CDT
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market--and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
NTRR: Cannabis Industry Crowns First Billionaire as Investor Demand Skyrockets
Business Wire - Mon Mar 17, 5:28AM CDT
As investors flock to emerging companies in the fast-growing U.S. cannabis industry, Neutra Corp. (OTCBB: NTRR) is working to capitalize on demand by developing incredible new product innovations for a diverse herbal marketplace.
Cannabis Market Continues Rapid Growth: Advancer with Recent Acquisitions Moves Forward to Become Full Reporting Company
PR Newswire - Wed Mar 12, 8:05AM CDT
The Medical Marijuana and Cannabis Industries forge ahead with indications of reaching a point of public acceptance as TV & radio ads are getting more air time. The bustling industry shows no signs of slowing down as the following companies continue to forge on with lessening restrictions: The CannaBusiness Group, Inc. (OTC: CBGI), Cannabis Science, Inc. (OTC: CBIS), GW Pharmaceuticals plc (NASDAQ: GWPH), MediSwipe, Inc. (OTC: MWIP) and Easton Pharmaceuticals Inc. (OTC: EAPH)
Cannabis Science (CBIS) Announces Investors In Private Placement Include Weedmaps and Dutch Investment Company; Weedmaps and CBIS to Develop Joint Ventures and Marketing Relationship
PR Newswire - Wed Mar 12, 7:29AM CDT
(CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announces that the investors acquiring $500,000 of the recent private placement included Weedmaps Media Inc. (Weedmaps), the world's largest online guide for medical cannabis patients, and an Amsterdam-based investment company. The full $1,000,000 private placement has been paid into the Company bank account.
NTRR Develops New Innovations to Capitalize on America's Cannabis Tipping Point
Business Wire - Wed Mar 12, 4:00AM CDT
As the cannabis industry in the U.S. rapidly approaches a regulatory tipping point, Neutra Corp. (OTCBB: NTRR) is hard at work marketing and developing top technological innovations designed to dramatically improve efficiency across the fast-growing market.
Beware of Getting High on Marijuana Stocks
at The Street - Tue Mar 11, 1:27PM CDT
Investing in hot growth stocks at high prices often ends badly.
Cannabis Science (CBIS) Acknowledges Dr. Sanjay Gupta, CNN Chief Medical Correspondent, for Objectively Addressing Treatment Benefits of Cannabis for Several Critical Ailments in Tonight's CNN Special: 'Weed 2'
PR Newswire - Tue Mar 11, 6:47AM CDT
Cannabis Science, Inc., (NASDAQ OTCQB: CBIS) a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds CNN's Dr. Sanjay Gupta for continuing to bring to public attention the medical value of cannabis to patients and the challenges that patients face in seeking cannabis-based life-savings treatments.
Cannabis Science (CBIS) Closes Recently Announced $1 Million PPM Financing To Fund Research and Development In the U.S.A. and Europe; Funding Effort Fully Subscribed
PR Newswire - Fri Mar 07, 9:19AM CST
(CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, closes the recently announced, February 20, 2014, financing for $1,000,000.00 through a private placement with the pricing set at $0.25 per share for Section 144 restricted shares coupled with a two-year warrant for $0.50 per share to comprise a complete unit offering.
Cannabis Capital Corp. (CBCA) Confirms Approval of Name Change with FINRA and Key Executive Appointments; Announces New Trading Symbol 'CBCA'
PR Newswire - Tue Mar 04, 10:26AM CST
Cannabis Capital Corp. (CBCA) fka World Stevia Corp (WSTV) is a Company focused on high-growth acquisitions within the Cannabis Industry.
Cannabis Science (CBIS) Expands into Spanish Market; Specific Focus on Medical Research and Studies
PR Newswire - Fri Feb 28, 9:52AM CST
(OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announces it has been in confidential negotiations for several months with key players in Spain to expand into the Spanish market to conduct cannabis research and other operations. The initial agreement has been signed and more information will be provided. Spain's population is approximately 47 million and has a significant cannabis and hemp market.
Research Report: AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5svvq/aids_related) has announced the addition of the "AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014" report to their offering. 'AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma. Scope - A snapshot of the global therapeutic scenario for AIDS - Related Kaposi's Sarcoma. - A review of the AIDS - Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the AIDS - Related Kaposi's Sarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction AIDS - Related Kaposi's Sarcoma Overview Therapeutics Development Pipeline Products for AIDS - Related Kaposi's Sarcoma - Overview Pipeline Products for AIDS - Related Kaposi's Sarcoma - Comparative Analysis AIDS - Related Kaposi's Sarcoma - Therapeutics under Development by Companies AIDS - Related Kaposi's Sarcoma - Pipeline Products Glance Clinical Stage Products Early Stage Products AIDS - Related Kaposi's Sarcoma - Products under Development by Companies AIDS - Related Kaposi's Sarcoma - Companies Involved in Therapeutics Development AIDS - Related Kaposi's Sarcoma - Therapeutics Assessment Drug Profiles aldoxorubicin - Drug Profile paclitaxel nanosomal - Drug Profile CS-TATI-1 - Drug Profile interferon alfa-2a biosimilar - Drug Profile interferon alfa-2b - Drug Profile interferon alfa-2a - Drug Profile R&D Progress Featured News & Press Releases Appendix Companies Mentioned Aphios Corporation CytRx Corporation Cannabis Science, Inc. Xiamen Amoytop Biotech Co., Ltd. Biogenomics For more information visit http://www.researchandmarkets.com/research/k5...ds_related About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cannabis Science Negotiates $1 Million Financing for Progression of Products and Start of Observational Trials
PR Newswire - Thu Feb 20, 9:37AM CST
(OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, has agreed to finance $1 million to satisfy its current capital requirements. Cannabis Science is raising the $1 million through private placement. The pricing is set at $0.25 per share for 144 restricted shares coupled with a one-year warrant for $0.50 per share to comprise a complete unit offering.
Pandora shares start to bounce while Cannabis Science announces partnership with Green Technologies
ACCESSWIRE - Tue Feb 18, 11:29PM CST
Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/
Cannabis Science (CBIS) Signs Partnership Agreement with Michigan Green Technologies, LLC to Focus on Reform and Proper Implementation of Cannabis and Commercial Hemp Programs for the State of Michigan
PR Newswire - Thu Feb 13, 8:36AM CST
Cannabis Science, Inc. (NASD OTC: CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, is proud to announce its new partnership with Michigan Green Technologies, LLC that has a broad focus on the reform and proper implementation of state approved cannabis and commercial hemp programs with comprehensive seed to sale process to include cultivation; studies; medical testing; manufacturing; a taxation model; commercial and consumer distribution; education; and clinical research.
Penske Automotive Reports Record Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Feb 13, 6:33AM CST
Penske Automotive Group, Inc. (NYSE
AG), an international transportation services company, announced today the highest fourth quarter and full year 2013 income from continuing operations and related earnings per share in company history. For the fourth quarter, income from continuing operations attributable to common shareholders increased 19.3% to $61.7 million and related earnings per share increased 19.3% to $0.68 per share when compared to the same period last year.
The Zacks Analyst Blog Highlights:BP, Tesoro, Apache, Anadarko Petroleum and FMC Technologies
PR Newswire - Wed Feb 12, 8:30AM CST
CHICAGO, Feb. 12, 2014 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the BP plc (NYSE:BP-Free Report), Tesoro Corp. (NYSE:TSO-Free Report), Apache Corp. (NYSE:APA-Free Report), Anadarko Petroleum Corp. (NYSE:APC-Free Report) and FMC Technologies Inc. (NYSE:FTI-Free Report).
Economic Benefit of Hemp Legalization Could Be Overestimated: (OTC PINK: HEMP), Cannabis Science Inc. (OTCQB: CBIS), Cannabis Solutions (OTCQB: CANN), Medbox, Inc. (OTC PINK: MDBX)
ACCESSWIRE - Wed Feb 12, 8:29AM CST
Is the legalization of hemp the potential economic windfall some predict?
Enertopia Announces Dr. Robert Melamede Ph.D. Joins Advisory Board
ACCESSWIRE - Wed Mar 26, 7:05AM CDT
VANCOUVER, BC / ACCESSWIRE / March 26, 2014 / Enertopia Corporation (ENRT) on the OTCBB and (TOP) on the CSE (the "Company" or "Enertopia") is very pleased to announce that Dr. Robert Melamede, Ph.D. and current President at Cannabis Science (CBIS) has joined the Advisory board of Enertopia.
Cannabis Science Finalizes $1 Million in New Financing
ACCESSWIRE - Wed Mar 19, 10:22AM CDT
A developer of cannabis-based pharmaceutical products Cannabis Science Inc. (NASDAQ OTC: CBIS) announced that it has finalized its $1,000,000 private placement and the funds have already been put into the bank.
Cannabis Science (CBIS) Applauds Unprecedented United States Federal Government Approval of University Study of Medical Cannabis for Veterans Suffering from PTSD
PR Newswire - Wed Mar 19, 9:03AM CDT
Cannabis Science, Inc. (NASDAQ OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds federal government approval of a University of Arizona study of efficacy of medical cannabis in treating post traumatic stress disorder (PTSD). Cannabis Science sees this approval by the U.S. Department of Health and Human Services as a watershed moment for federal authorization of medical cannabis research.
NTRR: Cannabis Market Growth Poised to Outpace Smartphones
Business Wire - Wed Mar 19, 4:00AM CDT
Cannabis is among the fastest-growing markets in the U.S., poised to outpace the expansion of the global smartphone market--and Neutra Corp. (OTCBB: NTRR) is readying a diverse product line to capitalize on that growth.
NTRR: Cannabis Industry Crowns First Billionaire as Investor Demand Skyrockets
Business Wire - Mon Mar 17, 5:28AM CDT
As investors flock to emerging companies in the fast-growing U.S. cannabis industry, Neutra Corp. (OTCBB: NTRR) is working to capitalize on demand by developing incredible new product innovations for a diverse herbal marketplace.
Cannabis Market Continues Rapid Growth: Advancer with Recent Acquisitions Moves Forward to Become Full Reporting Company
PR Newswire - Wed Mar 12, 8:05AM CDT
The Medical Marijuana and Cannabis Industries forge ahead with indications of reaching a point of public acceptance as TV & radio ads are getting more air time. The bustling industry shows no signs of slowing down as the following companies continue to forge on with lessening restrictions: The CannaBusiness Group, Inc. (OTC: CBGI), Cannabis Science, Inc. (OTC: CBIS), GW Pharmaceuticals plc (NASDAQ: GWPH), MediSwipe, Inc. (OTC: MWIP) and Easton Pharmaceuticals Inc. (OTC: EAPH)
Cannabis Science (CBIS) Announces Investors In Private Placement Include Weedmaps and Dutch Investment Company; Weedmaps and CBIS to Develop Joint Ventures and Marketing Relationship
PR Newswire - Wed Mar 12, 7:29AM CDT
(CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announces that the investors acquiring $500,000 of the recent private placement included Weedmaps Media Inc. (Weedmaps), the world's largest online guide for medical cannabis patients, and an Amsterdam-based investment company. The full $1,000,000 private placement has been paid into the Company bank account.
NTRR Develops New Innovations to Capitalize on America's Cannabis Tipping Point
Business Wire - Wed Mar 12, 4:00AM CDT
As the cannabis industry in the U.S. rapidly approaches a regulatory tipping point, Neutra Corp. (OTCBB: NTRR) is hard at work marketing and developing top technological innovations designed to dramatically improve efficiency across the fast-growing market.
Beware of Getting High on Marijuana Stocks
at The Street - Tue Mar 11, 1:27PM CDT
Investing in hot growth stocks at high prices often ends badly.
Cannabis Science (CBIS) Acknowledges Dr. Sanjay Gupta, CNN Chief Medical Correspondent, for Objectively Addressing Treatment Benefits of Cannabis for Several Critical Ailments in Tonight's CNN Special: 'Weed 2'
PR Newswire - Tue Mar 11, 6:47AM CDT
Cannabis Science, Inc., (NASDAQ OTCQB: CBIS) a U.S. Company specializing in cannabis formulation-based drug development and related consulting, applauds CNN's Dr. Sanjay Gupta for continuing to bring to public attention the medical value of cannabis to patients and the challenges that patients face in seeking cannabis-based life-savings treatments.
Cannabis Science (CBIS) Closes Recently Announced $1 Million PPM Financing To Fund Research and Development In the U.S.A. and Europe; Funding Effort Fully Subscribed
PR Newswire - Fri Mar 07, 9:19AM CST
(CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, closes the recently announced, February 20, 2014, financing for $1,000,000.00 through a private placement with the pricing set at $0.25 per share for Section 144 restricted shares coupled with a two-year warrant for $0.50 per share to comprise a complete unit offering.
Cannabis Capital Corp. (CBCA) Confirms Approval of Name Change with FINRA and Key Executive Appointments; Announces New Trading Symbol 'CBCA'
PR Newswire - Tue Mar 04, 10:26AM CST
Cannabis Capital Corp. (CBCA) fka World Stevia Corp (WSTV) is a Company focused on high-growth acquisitions within the Cannabis Industry.
Cannabis Science (CBIS) Expands into Spanish Market; Specific Focus on Medical Research and Studies
PR Newswire - Fri Feb 28, 9:52AM CST
(OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, announces it has been in confidential negotiations for several months with key players in Spain to expand into the Spanish market to conduct cannabis research and other operations. The initial agreement has been signed and more information will be provided. Spain's population is approximately 47 million and has a significant cannabis and hemp market.
Research Report: AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014
M2 - Mon Feb 24, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/k5svvq/aids_related) has announced the addition of the "AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014" report to their offering. 'AIDS - Related Kaposi's Sarcoma - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma. Scope - A snapshot of the global therapeutic scenario for AIDS - Related Kaposi's Sarcoma. - A review of the AIDS - Related Kaposi's Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the AIDS - Related Kaposi's Sarcoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction AIDS - Related Kaposi's Sarcoma Overview Therapeutics Development Pipeline Products for AIDS - Related Kaposi's Sarcoma - Overview Pipeline Products for AIDS - Related Kaposi's Sarcoma - Comparative Analysis AIDS - Related Kaposi's Sarcoma - Therapeutics under Development by Companies AIDS - Related Kaposi's Sarcoma - Pipeline Products Glance Clinical Stage Products Early Stage Products AIDS - Related Kaposi's Sarcoma - Products under Development by Companies AIDS - Related Kaposi's Sarcoma - Companies Involved in Therapeutics Development AIDS - Related Kaposi's Sarcoma - Therapeutics Assessment Drug Profiles aldoxorubicin - Drug Profile paclitaxel nanosomal - Drug Profile CS-TATI-1 - Drug Profile interferon alfa-2a biosimilar - Drug Profile interferon alfa-2b - Drug Profile interferon alfa-2a - Drug Profile R&D Progress Featured News & Press Releases Appendix Companies Mentioned Aphios Corporation CytRx Corporation Cannabis Science, Inc. Xiamen Amoytop Biotech Co., Ltd. Biogenomics For more information visit http://www.researchandmarkets.com/research/k5...ds_related About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cannabis Science Negotiates $1 Million Financing for Progression of Products and Start of Observational Trials
PR Newswire - Thu Feb 20, 9:37AM CST
(OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, has agreed to finance $1 million to satisfy its current capital requirements. Cannabis Science is raising the $1 million through private placement. The pricing is set at $0.25 per share for 144 restricted shares coupled with a one-year warrant for $0.50 per share to comprise a complete unit offering.
Pandora shares start to bounce while Cannabis Science announces partnership with Green Technologies
ACCESSWIRE - Tue Feb 18, 11:29PM CST
Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/
Cannabis Science (CBIS) Signs Partnership Agreement with Michigan Green Technologies, LLC to Focus on Reform and Proper Implementation of Cannabis and Commercial Hemp Programs for the State of Michigan
PR Newswire - Thu Feb 13, 8:36AM CST
Cannabis Science, Inc. (NASD OTC: CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, is proud to announce its new partnership with Michigan Green Technologies, LLC that has a broad focus on the reform and proper implementation of state approved cannabis and commercial hemp programs with comprehensive seed to sale process to include cultivation; studies; medical testing; manufacturing; a taxation model; commercial and consumer distribution; education; and clinical research.
Penske Automotive Reports Record Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Feb 13, 6:33AM CST
Penske Automotive Group, Inc. (NYSE
AG), an international transportation services company, announced today the highest fourth quarter and full year 2013 income from continuing operations and related earnings per share in company history. For the fourth quarter, income from continuing operations attributable to common shareholders increased 19.3% to $61.7 million and related earnings per share increased 19.3% to $0.68 per share when compared to the same period last year. The Zacks Analyst Blog Highlights:BP, Tesoro, Apache, Anadarko Petroleum and FMC Technologies
PR Newswire - Wed Feb 12, 8:30AM CST
CHICAGO, Feb. 12, 2014 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the BP plc (NYSE:BP-Free Report), Tesoro Corp. (NYSE:TSO-Free Report), Apache Corp. (NYSE:APA-Free Report), Anadarko Petroleum Corp. (NYSE:APC-Free Report) and FMC Technologies Inc. (NYSE:FTI-Free Report).
Economic Benefit of Hemp Legalization Could Be Overestimated: (OTC PINK: HEMP), Cannabis Science Inc. (OTCQB: CBIS), Cannabis Solutions (OTCQB: CANN), Medbox, Inc. (OTC PINK: MDBX)
ACCESSWIRE - Wed Feb 12, 8:29AM CST
Is the legalization of hemp the potential economic windfall some predict?
